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Abstract
HIV-1 disease progression is associated with persistent immune activation. However, the nature of this association is
incompletely understood. Here, we investigated immune activation in the CD4 T cell compartment of chronically HIV-1
infected individuals from Rakai, Uganda. Levels of CD4 T cell activation, assessed as co-expression of PD-1, CD38 and HLA-
DR, correlated directly to viral load and inversely to CD4 count. Deeper characterization of these cells indicated an effector
memory phenotype with relatively frequent expression of Ki67 despite their PD-1 expression, and levels of these cells were
inversely associated with FoxP3+ regulatory T cells. We therefore use the term deregulated effector memory (DEM) cells to
describe them. CD4 T cells with a DEM phenotype could be generated by antigen stimulation of recall responses in vitro.
Responses against HIV-1 and CMV antigens were enriched among the DEM CD4 T cells in patients, and the diverse Vb
repertoire of DEM CD4 T cells suggested they include diverse antigen-specificities. Furthermore, the levels of DEM CD4 T
cells correlated directly to soluble CD14 (sCD14) and IL-6, markers of innate immune activation, in plasma. The size of the
activated DEM CD4 T cell subset was predictive of the rate of disease progression, whereas IL-6 was only weakly predictive
and sCD14 was not predictive. Taken together, these results are consistent with a model where systemic innate immune
activation and chronic antigen stimulation of adaptive T cell responses both play important roles in driving pathological
CD4 T cell immune activation in HIV-1 disease.
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Introduction
HIV-1 disease progression is associated with chronic activation
of the immune system [1,2,3,4,5,6,7,8] (reviewed in [9,10]), but
the mechanisms involved remain incompletely understood.
Unraveling the causes, interactions, and mechanisms underlying
immune activation is thus central to the understanding of HIV
pathogenesis and one of the major ‘‘roadblocks’’ in HIV research
[11]. One proposed cause of systemic immune activation is
microbial product translocation across a gut barrier damaged by
intense HIV replication [12,13]. Brenchley et al. found that
lipopolysaccharide (LPS) and soluble CD14 (sCD14), thought to
be correlative markers of microbial translocation, in plasma were
associated with CD8 T cell activation in chronic HIV-1 infection
[12]. A role for microbial translocation is supported by findings in
natural SIV infection of African green monkeys and sooty
mangabeys [14,15,16]. However, high levels of LPS in rhesus
monkeys may not predict faster disease progression [17]. A second
proposed cause behind chronic activation is direct innate
recognition of viral RNA and subsequent activation of the type I
interferon (IFN) response, and this is also supported by data from
natural hosts of SIV, which exhibit a lower and less sustained
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profiling of monocytes from HIV-1 infected patients suggested that
IFNa may be an important factor in the activation of these cells
[21]. A third possible cause of activation in the T cell
compartment is direct TCR-mediated recognition of antigens,
and fourth possibility is bystander activation, which may be driven
by the aforementioned mechanisms or have other causes [22]. It is
important to recognize that these four different suggested
mechanisms are not mutually exclusive.
Immune cell exhaustion plays a role in loss of control of HIV-1
viremia. Programmed death 1 (PD-1, or CD279), is a negative
regulator of T cell activation [23]. The association between PD-1
expression and poor function of HIV-specific T cells and aspects of
HIV disease has been observed for CD8 T cells [24,25,26,27], and
for CD4 T cells [28]. Blocking of the PD-1 pathway in vivo in
macaques results in increased SIV-specific T cell function and
longer survival of the animals [29,30]. In summary, uncontrolled
activation combined with exhaustion and excessive negative
feedback regulation contribute to a situation with poor immune
control of HIV.
FoxP3+ regulatory T cells (Tregs) are important for maintaining
immune tolerance and for avoiding inappropriate immune
activation and autoimmunity [31]. In HIV-1 infection, Tregs
probably have a beneficial function by limiting the damage of
immune activation [32,33,34,35]. However, loss of Tregs from
blood may represent redistribution to lymphoid tissues where they
might interfere with T cell control of HIV-1 replication [36,37].
The beneficial role of Tregs in HIV-1 disease is thus not entirely
clear-cut. In this study, we investigated aspects of immune
activation and immune regulation with the aim to better
understand pathological immune activation in the CD4 T cell
compartment of HIV-1 infected patients in sub-Saharan Africa,
and to better understand relationships between CD4 T cell
activation and possible causes of such activation.
Materials and Methods
Study cohort and samples
Study participants aged 15–49 years were enrolled in a
prospective community-based cohort to assess the prevalence
and incidence of HIV-1 infection in Rakai District, Uganda, from
1998 until 2004 (Table 1) [38,39,40]. Infected subjects were
identified between 1997 and 2002 with continued annual follow
up through 2008. The study was approved by institutional review
boards in the US and Uganda: The institutional Review Boards of
Uganda’s National Council for Science and Technology (UNCST)
and the Uganda Virus Research Institute’s Science and Ethics
Committee, as well as the Division of Human Subjects Protection
at the Walter Reed Army Institute of Research. Written informed
consent given by all participants, and written informed consent
was obtained from the parent or legal guardian of those aged 17.
PBMC samples were isolated and cryopreserved as described [41],
from 103 randomly selected HIV-1 sero-positive individuals and
40 community-matched sero-negative controls. No patients were
on antiretroviral therapy. HIV-1 testing was performed as
described [40]. Positive samples were subjected to the Amplicor
HIV-1 Monitor test, version 1.5 (Roche Diagnostics, Indianapolis,
IN).
Flow cytometry and mAbs
Cryopreserved specimens were thawed and washed, and
counts and viability assessed on the Guava PCA (Guava
Technologies, Hayward, CA), using Guava ViaCount reagent.
Cells washed with PBS/BSA buffer, and stained at 4uCf o r
30 min in 96-well V-bottom plates in the dark. mAbs used in flow
cytometry; anti-HLA-DR FITC or V450, IgG2a FITC, anti-PD-
1 PE or IgG1 PE, anti-CD3 PerCP-Cy5.5 or APC-H7, anti-
CCR7 PE-Cy7, anti-CD8 PE-Cy7 or PE-TR or Qdot605, anti-
CD38 APC or IgG1 APC, anti-CD4 Pacific Blue (PB) (all from
BD Biosciences, San Jose, CA), and Aqua Live/Dead Stain
(Invitrogen, Carlsbad, CA). The anti-PD-1 PE (clone EH12) was
a kind gift from Maria Jaimes at BD Biosciences. Anti-CD19 PE-
Cy5, and anti-CD45RO eF650NC were from eBioscience (San
Diego, CA), and anti-CD28 PerCP-Cy5.5 was from BioLegend
(San Diego, CA). Anti-CD4 Qd605, and anti-CD14 PE-Cy5 were
from Invitrogen. Anti-CD4 ECD was from Beckman Coulter
(Brea, CA). For assessment of Ki67 expression, cells were fixed
and permeabilized with eBioscience fix/perm for 60 min at 4uC
and stained with anti-Ki67 FITC (BD Bioscience) for 30 min.
Tregs were identified using anti-CD25 PE, anti-CD3 PerCP-
Cy5.5, anti-CD127 APC, and anti-CD4 PB (all from BD
Biosciences). Samples were washed, permeabilized and fixed
using a kit optimized for FoxP3 staining (eBioscience, San Diego,
CA), and stained with anti-FoxP3 Alexa Fluor 488 (BioLegend
San Diego, CA). Flow cytometry data was acquired using a BD
LSR II instrument or a BD FACS Canto II instrument (BD
Table 1. Study population descriptive statistics.
HIV-1 negative HIV-1 positive
Subjects, no. 40 103
Female, no. (%) 20 (50%) 65 (63%)
Male, no. (%) 20 (50%) 38 (37%)
Age, median years (range) 29 (20–42) 30 (17–53)
Time from sero-conversion, median days (range) NA 913 (22–2284)
Viral load, median copies/ml (range) NA 35,828 (528–1,685,638
CD4 absolute count, median cells/ml (range) NA 513 (1–1385)
HIV-1 subtype A, no. (%) NA 35 (34%)
HIV-1 subtype D, no. (%) NA 68 (66%)
Hepatitis B virus, no. (%) 3 (8%) 8 (8%)
Syphilis, no. (%) 3 (8%) 9 (9%)
NA indicates not applicable.
doi:10.1371/journal.pone.0018779.t001
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using FACS MultiSET System and run on a FACSCalibur using
the single platform Multi-test 4-color reagent in combination with
TruCount tubes (BD Biosciences).
IL-1b, IL-12p70, TNFa, IL-10, IL-6 and IL-8 were measured
in plasma using a Human Inflammatory Cytokine Bead Array (BD
Biosciences), and a FACSCalibur flow cytometer. sCD14 was
measured in plasma using a quantitative sandwich enzyme
immunoassay (R&D Systems, Minneapolis, MN). Absorbance
was measured using a BioTek ELx800 plate reader and analyzed
using the KC4 data analysis software (BioTek, Winooski, VT).
To examine Vb distribution of T cells, cryopreserved PBMC
specimens were thawed and stained for HLA-DR, PD-1, CD3,
CD38, CD4, CD8 and Aqua Live/Dead. Anti-TCR Vbs included
mAbs against Vb1, Vb2, Vb3, Vb5.1, Vb5.2, Vb7, Vb8, Vb11,
Vb12, Vb13.1, Vb13.6, Vb14, Vb16, Vb17, Vb20, Vb21.3, and
Vb22 conjugated to FITC (all from Beckman Coulter). After
incubation, samples were washed 2 times and fixed in 2%
formaldehyde before acquisition.
Functional assays
To assess the generation of immune activation in vitro, PBMC
from HIV-1 sero-negative donors were thawed and 1610
5 cells
per well incubated in 96-well U-bottom plates with Adenovirus
serotype 5 (Ad5) hexon peptides (Miltenyi Biotec Inc., Auburn,
CA) at 1 mg/ml, Candida albicans allergenic extract (Greer
laboratories Inc., Lenoir, NC) at a 1:500 dilution, Cytomegalo-
virus (CMV) viral lysate (Advanced Biotechnologies Inc.,
Columbia, MD) at 0.5 mg/ml, CMVpp65 PepMix (JPT Peptide
Technologies GmbH, Berlin, Germany) at 1 mg/ml, Concanav-
alin-A (ConA) (Sigma, St. Louis, MO) at 1.25 mg/ml, Phytohe-
magglutinin (PHA) (Sigma) at 2 mg/ml, Pokeweed Mitogen
(PWM) (Sigma) at 20 mg/ml, and Staphylococcal Enterotoxin B
(SEB) (Sigma) at 10 ng/ml for 3-6 days. Supernatants were
collected and cells were stained for expression of CD38, HLA-
DR, and PD-1. To assess antigen-specific CD4 T cell responses,
PBMC were thawed and cultured overnight (12 hrs) with HIV-1
subtype A Gag peptides (1 mg/ml), HIV-1 subtype A whole
inactivated virus (HIVWIV) (Lot P4039) and microvesicles (Lot
P3772) at 500 ng/ml (courtesy of Jeff Lifson (NCI Frederick,
MD), CMVpp65 peptides, CMV lysate, or SEB. Brefeldin A
(Sigma, St. Louis, MO) was present during the final 6 hrs of
incubation. After incubation, samples were fixed, washed, and
permeabilized using BD PERM Wash (BD Biosciences), and
stained with anti-IFNc PB (eBiosciences) and anti-TNFa PE-Cy7
(BD Biosciences) before acquisition on an BD LSRII cytometer
(BD Biosciences).
Statistical analysis
Cytometry analysis was performed using FlowJo version 8.5
(Tree Star, Ashland, OR). All statistical analysis was performed
using Graph Pad Prism version 5.0a for Mac OSX (GraphPad
S o f t w a r e ,L aJ o l l a ,C A ) .C o m p a r i s o n sb e t w e e ng r o u p sw e r e
performed using Fisher’s exact test for categorical data. Direct
comparisons between two groups were performed using the
non-parametric Mann-Whitney U test. Associations between
groups were determined by Spearman’s rank correlation.
Kaplan-Meier survival curves were calculated from the
estimated time of infection to reaching CD4 counts,250
cells/ml of whole blood. For paired observations a paired t test
was used. P values,0.05 were considered statistically significant.
Statistical methods and analyses were reviewed by EmpiriStat,
Inc. (Mount Airy, MD).
Results
Activated CD4 T cells with co-ordinate expression of
HLA-DR, CD38, and PD-1 are deregulated effector
memory cells and elevated in chronically HIV-1 infected
patients in Rakai, Uganda
HIV-1 negative (n=40) and HIV-1 positive (n=103) individ-
uals from a cohort in Rakai, Uganda, were chosen to study CD4 T
cell activation in untreated HIV-1 infection (Table 1). Activated
CD4 T cells expressing CD38 and HLA-DR were identified by
flow cytometry (Figure 1A). These cells were largely positive for
PD-1, suggesting an exhausted phenotype. The CD38+
HLA2DR+PD-1+ CD4 T cells were significantly elevated in
HIV-1 infected patients as compared to healthy donors (P,0.001)
(Figure 1B). To further characterize the PD-1+HLA-DR+CD38+
CD4 T cell subset, we analyzed their expression of CD45RO,
CCR7, CD28, and Ki67. These cells were largely CD45RO+,
CD28+, and negative or dim for CCR7. In addition, a proportion
expressed the proliferation marker Ki67 (Figure 1C). This
expression pattern is consistent with an effector memory profile
that retains the proliferative capacity, despite the expression of
PD-1.
Regulatory activity mediated by Tregs is important to limit
inappropriate or persistent immune activation [31]. The
CD4+CD25+CD127-FoxP3+ Treg compartment was reduced in
HIV-1 infected subjects (Figure 2A), but the Treg levels did not
correlate with the CD4 count (Figure 2B), or viral load (Figure 2C).
However, there was an inverse relationship between FoxP3+ Tregs
and PD-1+HLA-DR+CD38+ CD4 T cells (r=20.444, P,0.001)
(Figure 2D). The Ki67+ effector memory phenotype of the PD-
1+HLA-DR+CD38+ CD4 T cells, and the association between
these cells and the decline in the Treg compartment, together
supports a model in which these cells are deregulated effector
memory (DEM) cells.
Correlates between DEM CD4 T cell expansion and HIV-1
disease
We next investigated associations between immune activation in
CD4 T cells and aspects of HIV-1 disease in this cohort. The size
of the DEM CD4 T cell subset was directly correlated with viral
load (r=0.549, P,0.001) (Figure 3A), and inversely correlated
with CD4 count (r=20.603, P,0.001) (Figure 3B). Next, the
ability to predict progression to AIDS in this cohort using the
DEM CD4 T cell phenotype was assessed. AIDS was defined as
CD4 counts below 250 cells/ml. Patients were divided into two
groups for having levels of DEM CD4 T cells above or below the
median (6%) (Figure 3C). Values below the median overlapped
with the range observed in uninfected subjects. Patients with levels
above 6% of CD4 T cells were more likely to progress to AIDS
(log-rank P=0.001, HR 0.336, 95% CI=0.173–0.653). Notably,
the two groups with high and low levels of DEM CD4 T cells did
not differ significantly in their estimated time since infection (data
not shown). Thus, the DEM phenotype identifies a state of
pathological immune activation in the CD4 T cell compartment
which is associated with HIV-1 disease progression.
Associations between measures of HIV disease
progression and soluble CD14 and IL-6, measures of
innate immune activation, in plasma
CD14 is released from monocytes upon activation, and soluble
CD14 (sCD14) in plasma can be used as a marker of such
activation in response to innate stimuli [12,42]. sCD14 was
elevated in HIV-1 infected subjects as compared to uninfected
CD4 T Cell Activation in HIV Disease
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subjects correlated inversely with sCD14 in plasma (r=20.482,
P,0.001) (Figure 4B). There was also a weak positive correlation
between sCD14 levels and viral load (r=0.282, P=0.004)
(Figure 4C). Importantly, however, subjects with high and low
sCD14 levels did not differ in their AIDS-free survival during
clinical follow-up (Figure 4D). Similarly, patients with Treg levels
above or below the median percentage did not differ in their
AIDS-free survival (data not shown).
IL-1b, IL-12p70, TNFa, IL-10, IL-6 and IL-8 were measured
in plasma from HIV-1 infected and uninfected subjects, and IL-6
and IL-8 were found to be significantly elevated in the infected
group (Figure 4E and data not shown). However, only IL-6
showed an inverse correlation with CD4 counts (r=20.394,
P,0.001) (Figure 4F), and a weak positive association with viral
load (r=0.278, P=0.005) (Figure 4G). In contrast to the pattern
with sCD14, having above the median level of IL-6 in plasma was
a significant predictor of faster disease progression (log-rank
P=0.023, HR 0.462, 95% CI=0.238-0.900) (Figure 4H). In
summary, measures of innate immune activation, sCD14 and
IL-6, show a degree of association with HIV-1 disease. However,
these associations are weaker than those observed between CD4
count, viral load, AIDS-free survival, and the size of the DEM
CD4 T cell population.
Analysis of relationships between the DEM CD4 T cell
expansion and measures of innate immune activation
These data behooved us to next search for association between
the DEM CD4 T cell population, Tregs, sCD14 levels, and IL-6
Figure 1. PD-1, HLA-DR, and CD38 together identify an effector memory CD4 T cell subset elevated in HIV-1 infection.
(A) Identification of CD4 T cells co-expressing PD-1, HLA-DR and CD38 in HIV-1 infected and uninfected subjects. (B) Box and whisker plots showing
the median and 10–90 percentile percentage of CD38, HLA-DR and PD-1 triple-expression in CD4 T cells in HIV negative (n=40) and HIV positive
(n=103) subjects. (C) In order to assess the phenotype of the activated CD4 T cells, PBMC were analyzed by flow cytometry for the expression of
CD45RO, CCR7, CD28, and Ki67. Filled line represents CD4 cells triple-positive for CD38, HLA-DR, and PD-1, while dashed line represents data from the
overall CD4 compartment and empty filled line is the fluorescence minus one (FMO) control for that channel.
doi:10.1371/journal.pone.0018779.g001
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was directly associated with levels of sCD14 (r=0.443, P,0.001)
(Figure 5A), and levels of IL-6 (r=0.383, P,0.001) (Figure 5B).
The two measures of innate immune activation, IL-6 and sCD14,
were weakly correlated (r=0.323, P=0.001) (Figure 5C). Tregs
showed an inverse correlation with DEM CD4 T cells (r=20.444,
P,0.001), but no significant correlation with CD4 count and viral
load (Figure 2). Similarly, there was no correlation between Treg
levels, and levels of sCD14 or IL-6 (Figure 5D and E, respectively).
Thus, DEM CD4 T cell expansion is associated with both innate
immune activation and decline in circulating Tregs. However,
innate immune activation and changes in Tregs show no apparent
association.
Expansion of DEM CD4 T cells can be driven by antigen in
vitro
We next investigated factors that might be involved in driving
the expansion of PD-1+HLA-DR+CD38+ CD4 T cells. To begin
to address the hypothesis that high antigen loads may drive this
population, we first stimulated PBMC from healthy donors with a
set of different recall antigens, mitogens and superantigen
(Figure 6A). Several of the stimuli, in particular CMV and
Candida antigens, provoked significant expansions of triple-
positive CD4 T cells (Figure 6B).
In a second approach, we assessed CD4 T cell responses in the
HIV-1 infected patients against CMV, HIV and SEB (Figure 6C).
Responses against all these antigens were measured by intracel-
lular co-staining for both IFNc and TNFa, and found to be
enriched in the DEM CD4 T cells as compared to the overall CD4
compartment. These data collectively indicate that the DEM CD4
T cell phenotype may be driven by antigen stimulation.
DEM CD4 T cells display a non-biased Vb distribution
Enrichment of antigen-specific responses in the DEM CD4 T
cells is consistent with an antigen-driven expansion of these cells.
Nevertheless, the percentages of antigen-specific responses in the
DEM CD4 T cells were modest. We therefore next investigated
the TCR Vb distribution of these cells, where a strongly biased Vb
distribution would be consistent with a narrowly antigen-driven
expansion. Surprisingly, the DEM CD4 T cells displayed a diverse
Vb distribution very similar to the overall CD4 T cell
compartment (Figure 6D). Taken together, these results support
a model where a broad array of antigens support the generation of
diverse DEM CD4 T cells in the context of the innate immune
activation milieu that persists in chronically HIV-1 infected
individuals.
Discussion
In the present study, we aimed to better understand persistent
immune activation in the CD4 T cell compartment of HIV-1
infected patients in rural Uganda, and to investigate relationships
Figure 2. Inverse correlation between FoxP3+ regulatory T cells and PD-1+CD38+HLA-DR+ CD4 T cells. (A) Box and whisker plots
showing the median and 10–90 percentile percentage of FoxP3+CD25+CD127- regulatory CD4 T cells in HIV negative and HIV positive subjects.
(B) Spearman rank correlation between regulatory CD4 T cells and CD4 absolute T cell counts. (C) Spearman rank correlation between regulatory CD4
T cells and viral load. (D) Spearman rank correlation between regulatory CD4 T cells and CD38, HLA-DR and PD-1 triple-positive CD4 T cells in blood.
doi:10.1371/journal.pone.0018779.g002
Figure 3. Levels of deregulated effector memory CD4 T cells correlate to and predict HIV-1 disease progression. (A) Spearman rank
correlation between percentages of CD38, HLA-DR and PD-1 triple-expressing CD4 T cells and HIV-1 plasma viral load. (B) Spearman rank correlations
between percentages of CD38, HLA-DR and PD-1 triple-expressing CD4 T cells and CD4 counts. (C) Kaplan-Meier analysis comparing the time to AIDS,
as defined by CD4 T cell counts less than 250 cells/ml of whole blood. HIV-1 positive subjects with CD38, HLA-DR and PD-1 triple-expressing CD4 T
cells above the median (6%) were more likely to advance to AIDS (Log-rank =0.001, Hazard Ratio (HR) 0.336, 95% CI=0.173 to 0.653).
doi:10.1371/journal.pone.0018779.g003
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pathologically activated CD4 T cells have a Ki67+ effector
memory phenotype, and because they are activated despite their
expression of PD-1, and correlate inversely with FoxP3+ Treg
levels, we use the term deregulated effector memory (DEM) cells to
describe them.
Monocyte activation in response to microbial material results in
the release of sCD14, which is seen at elevated levels in infected
Figure 4. Associations between sCD14 and IL-6 levels in plasma and measures of HIV-1 disease progression. (A) Box and whisker plot
showing sCD14 levels in plasma from HIV-1 infected (n=103) and HIV-1 uninfected (n=40) subjects. Spearman rank correlations between sCD14 in
plasma and (B) CD4 absolute T cells counts, and (C) viral load. (D) Kaplan-Meier analysis comparing the time to AIDS. HIV-1 positive subjects with
sCD14 levels above and below the median (1939 ng/ml) were not statistically different (Log-rank P=0.185, Hazard Ratio (HR) 0.631, 95% CI=0.319 to
1.247). (E) Box and whisker plot showing IL-6 levels in plasma from HIV-1 infected (n=103) and HIV-1 uninfected (n=40) subjects. Spearman rank
correlations between IL-6 in plasma and (F) CD4 absolute T cells counts and (G) viral load. (H) Kaplan-Meier analysis comparing the time to AIDS. HIV-1
positive subjects with IL-6 levels above the median (3.2 pg/ml) more likely to advance to AIDS (Log-rank P=0.023, HR 0.462, 95% CI=0.238–0.900).
doi:10.1371/journal.pone.0018779.g004
Figure 5. sCD14 and IL-6 correlate with levels of deregulated effector memory CD4 T cells, but not with Tregs. (A) Spearman rank
correlation between sCD14 in plasma and CD38, HLA-DR and PD-1 triple-positive CD4 T cells in blood. (B) Spearman rank correlation between IL-6 in
plasma and CD38, HLA-DR and PD-1 triple-positive CD4 T cells. (C) Spearman rank correlation between IL-6 and sCD14 in plasma. (D) Spearman rank
correlation between Tregs and IL-6. (E) Spearman rank correlation between Tregs and sCD14 levels.
doi:10.1371/journal.pone.0018779.g005
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18779Figure 6. CD38+HLA-DR+PD-1+ cells can be driven by antigen in vitro, but display a non-biased Vb distribution in vivo. (A) Experiments
were conducted to assess the ability to generate the combined expression of CD38, HLA-DR, and PD-1 on CD4 T cells after three days of mitogen
stimulation, or six days of antigen or superantigen stimulation of PBMC from four healthy donors. Bars represent mean and standard error of the
mean. (B) Example PD-1 expression flow cytometry histogram and contour plot for CD38 and HLA-DR expression on CD4 T cells from one CMV non-
responder (top panels), and one CMV responder after six days of stimulation with CMV lysate. (C) In order to characterize the prevalence of antigen
CD4 T Cell Activation in HIV Disease
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e18779subjects[12,42].Wefound that sCD14correlated inverselywith CD4
counts and directly with DEM CD4 T cell levels. sCD14 also
correlated positively, albeit weakly, with viral load. Notably, however,
groups with high and low levels of sCD14 did not differ in their pace
of disease progression during clinical follow-up. IL-6 is released in
response to activation of innate cells, including monocytes, and
displayed correlations with CD4 counts and DEM CD4 T cells
similar to those of sCD14. Also in similarity with sCD14, the
correlation with viral load was very weak. However, in contrast to
sCD14, patients with high and low levels of IL-6 differed in their rate
of progression to AIDS during clinical follow-up. One might
therefore speculate that IL-6 is more likely than sCD14 to indicate
pathogenic processes in the innate immune system during chronic
untreated HIV-1 infection. Treg levels correlated inversely with
DEM CD4 T cells, but showed no correlation with CD4 count, viral
load, IL-6 or sCD14. Changes in Treg percentages thus appear to be
primarily associated with the activated DEM CD4 T cell expansion,
a n dl e s ss ot ot h eo t h e rm e a s u r e so fd i s e a s e .
We observed that the DEM CD4 T cell phenotype can be
driven in vitro by stimulation of healthy donor PBMC with recall
antigens for six days. In particular, stimulation with CMV and
Candida antigens resulted in effective expansion of such cells. In
addition, there was an enrichment of HIV-specific and CMV-
specific cells in the DEM CD4 T cell subset in patients. These
observations support a model where the DEM cell expansion is at
least partly antigen-driven. We were therefore surprised to find
that the TCR Vb distribution was not significantly different
between these cells and the rest of the CD4 compartment in HIV-
1 infected subjects. If the DEM CD4 T cells were strongly driven
by a few antigens, then one would expect a biased Vb distribution.
Since this was not the case, it seems likely that the expanded DEM
CD4 T cells are specific for a diverse array of antigens from HIV,
CMV, and other pathogens. We therefore suggest a model in
which the accumulation of DEM CD4 T cells is the result of
antigen-driven expansion under conditions when the immune
system is exposed to microbial material, including components of
HIV, driving innate immune activation.
The correlation between levels of IL-6 and DEM CD4 T cells,
albeit weak, initially suggested that this cytokine might be involved
in the generation or maintenance of these cells [43]. HIV-1
infection has long been associated with increased levels of IL-6
[44,45], and IL-6 can be produced by monocytes in response to
both LPS and the HIV-1 accessory protein Vpr [46], suggesting
that both viral and bacterial antigens could contribute to the
increased levels of this inflammatory cytokine. In the present
study, blocking of IL-6 and IL-6R or addition of exogenous IL-6 to
cultures had no measureable effect (data not shown). This does not
contradict a possible role of IL-6 during long-term exposure.
Another factor of interest, according to the hypothesis that
excessive TLR7/9 signaling in response to HIV RNA underlies
persistent immune activation, is type I IFNs [18,19,20]. However,
similar to the results with IL-6, we observed no effect by addition
of IFNa in cultures (data not shown). Of note, IFNa treatment
of HIV patients on successful ART co-infected with hepatitis C
virus was previously observed to reduce immune activation [47].
Similarly, we observed no effect on DEM cell expansion by adding
whole inactivated HIV to short-term in vitro cultures (data not
shown). Again, these observations do not contradict a pathogenic
contribution of type I IFNs in vivo, in particular as a co-factor
working together with other causes of activation.
In a previously published longitudinal study based on this
Ugandan cohort, soluble markers of innate immune activation in
plasma did not change over the course of HIV disease progression
[48]. The relationships between microbial translocation, chronic
activation of innate and adaptive immune cells, levels of cytokines
and other markers in plasma, and HIV disease progression are
thus very complex. However, the present study supports an
association between innate immune activation and expansion of
the DEM CD4 T cells. This CD4 T cell phenotype may identify
the cells, which are activated by chronic antigen stimulation in the
context of innate immune system activation by microbial
components. Such material may be derived from microbial
translocation, as well as from HIV virions. Here, levels of DEM
CD4 T cells correlated directly to HIV viral load, possibly
supporting a role for viral proteins or RNA in the expansion of
these cells.
The DEM CD4 T cells display a CD45RO+CCR7- effector
memory phenotype, and they express Ki67 at a higher rate than
the overall CD4 T cell compartment. The relatively frequent
expression of Ki67 suggests that this is an actively proliferating cell
subset despite the expression of PD-1, which is a negative regulator
of TCR signaling. The question arises as to what extent PD-1 is a
strong inhibitory receptor in CD4 T cells in vivo. One possibility is
that the negative signals mediated by PD-1 are counter balanced
by co-stimulation via CD28 [49].
The data presented in this paper are consistent with a model
where continuous exposure to microbial material, including
components of HIV, creates conditions permissive to the
expansion pathologically activated CD4 T cells with the DEM
phenotype. The accumulation of DEM CD4 T cells may result
from antigen-driven expansion under conditions of persistent
innate immune activation. Future studies to examine the
mediators of pathogenic T cell activation are needed to allow
the development of targeted therapies to alleviate activation and,
possibly, slow disease progression.
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specific cells in the CD38, HLA-DR and PD-1 triple-positive CD4 T cell subset, thawed PBMC were stimulated with HIV Gag peptide pool, whole
inactivated HIV-1 (HIVWIV), CMV pp65 peptide pool and lysate, and the superantigen SEB. Grouped columnar scatter plots for responses to Gag
peptides or whole inactivated virus (n=10), CMV lysate responders (n=18) and SEB responders (n=18). Cells co-expressing IFNc and TNFa were
considered positive in this assay. Data were analyzed using the paired t test. (D) In order to assess the TCR Vb repertoire of CD38+HLA-DR+PD-1+ CD4
T cells, the representation of 17 different Vb specificities were analyzed by flow cytometry. Grouped vertical bar graph showing the mean and
standard deviation for 10 HIV-1 infected patients. White bars represent the overall CD4 T cell compartment, while grey bars represent the CD38, HLA-
DR, and PD-1 triple-expressing CD4 T cells. There is no statistically significant difference in representation of any Vb between the two CD4 T cell
subsets.
doi:10.1371/journal.pone.0018779.g006
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